Research raises questions about how eager people will be to take COVID-19 vaccine

  • September 18, 2020
  • By Jill Young Miller
  • 4 minute read

New research shows consumers strongly prefer “natural,” not synthetic, products to prevent ailments. Which presents a dilemma. Medical researchers are racing to create a vaccine for COVID-19. When they do, how receptive will consumers be?

Vaccines are far from “natural.”

“Vaccines are technically a treatment to prevent an ailment,” said Sydney Scott, Olin assistant professor of marketing. “Moreover, vaccines are unnatural insofar as humans create and alter them. Some people refuse vaccines as a preventative measure, preferring not to ‘interfere with nature.’”

Sydney Scott

As the world anxiously awaits a COVID-19 vaccine, however, perhaps consumers will view it as a curative for a societal problem, Scott said.

“Our research suggests that if consumers view a vaccine more like a curative to the epidemic, rather than as a preventative for the self, they will be more receptive toward it.”

Scott, an expert in consumer behavior and decision-making, is the lead author of “Consumers Prefer ‘Natural’ More for Preventatives Than for Curatives,” forthcoming in the Journal of Consumer Research.

Consumers’ beliefs

Consumers believe that natural products are safer and less potent than synthetic alternatives, the research found. And they care more about safety and less about potency when they’re trying to prevent problems.

“This research sheds light on when the marketing of ‘natural’ is most appealing to consumers,” Scott said.

Consumers often prefer natural versions of foods, medicines, personal care products and home products, according to the paper. “Natural” isn’t a legally defined and regulated term, but consumers’ definition is that a product has no additives and that humans haven’t tampered with it.

“This preference for natural is an increasingly important driver of consumers’ decisions,” Scott said.

Insulin, antibiotics, cortisone creams

In some cases, however, consumers abandon their preference for natural.

For example, people widely accept insulin, antibiotics, cortisone creams and synthetic stain removers, although they are evidently unnatural, according to the paper. “Thus, anecdotally, the preference for natural products looms larger in some situations than in others.”

The researchers focused on the relation between consumers’ judgments about naturalness and their beliefs about two important attributes—safety and potency. They examined when consumers prefer natural most strongly and why the variance in preference for natural occurs.

“Consumers widely desire natural products, but not always to the same degree,” Scott said. “We demonstrate that the preference for natural is particularly strong when consumers are preventing problems or illnesses compared to when they are curing the same problems or illnesses.”

Scott and coauthors Paul Rozin and Deborah Small, both of the University of Pennsylvania, present seven studies. One showed that consumers more strongly prefer the exact same natural product when preventing an ailment than when curing it. Another showed consumers search for and chose natural products to prevent versus treat cold symptoms.

Another, which examined consumers’ reports about their health choices over a year, found consumers prioritize naturalness in their preventative treatments more than in their curative treatments. And another showed that when consumers believed natural products were riskier and more potent than synthetic products, they preferred natural products for curing.

COVID-19

The research was developed with a focus on individuals making decisions for themselves among multiple treatment options (some natural, some synthetic). But the emergence of the COVID-19 pandemic raises important questions about the implications—and future directions—of their research.

For instance, the authors ask, do pandemics induce a macro-level version of a curative mindset?

“In other words, society may conclude that there already exists a problem (a widespread ailment) that needs to be cured, thereby placing more importance on potency relative to safety,” they write.

Relatedly, consumer acceptance of a prevention for pandemics and epidemics might be affected by the contagiousness of a disease, severity of a disease, scarcity of treatment options, and novelty of and lack of knowledge about the threat. And each might have downstream consequences on safety/potency tradeoffs consumers are willing to make.

Contributions

The paper makes several contributions. “Our primary contribution is to provide an organizing principle for explaining when consumers prefer natural products,” the authors write. The prevent/cure distinction explains variation in the preference for natural

  • across distinct product categories such as food and medicine,
  • within product categories such as different types of medicine,
  • and for the same product depending on whether consumers used it to prevent or to cure ailments.

“In doing so, our research not only generates new predictions, but also helps unify past descriptive findings under one theoretical framework.”

From an applied perspective, “the identified organizing principle can help marketers predict when and where the preference for natural is likely to loom large.”

Marketers and managers often must make decisions about when to invest in a natural brand or product line.

“Our research suggests that, all else equal, natural products are most popular when they are used for preventative purposes.”

About the Author


Jill Young Miller

Jill Young Miller

As research translator for WashU Olin Business School, my job is to highlight professors’ research by “translating” their work into stories. Before coming to Olin, I was a communications specialist at WashU’s Brown School. My background is mostly in newspapers including as a journalist for Missouri Lawyers Media, the Atlanta Journal-Constitution, The Washington Post and the Sun-Sentinel in South Florida.

Contact Us

For assistance in finding faculty experts, please contact Washington University Public Affairs.

Monday–Friday, 8:30 to 5 p.m.

Sara Savat, Senior News Director, Business and Social Sciences
314-935-9615
sara.savat@wustl.edu

 

Kurt Greenbaum,
Communications Director
314-935-7196
kgreenbaum@wustl.edu

Twitter: WUSTLnews